Detailed Overview Of Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer

Researchmoz added Most up-to-date research on "Detailed Overview Of Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer" to its huge collection of research reports.

Breast cancer remains a major global healthcare concern despite exceptional levels of public awareness about the disease. A lack of clear causative environmental factors and hereditary dispositioning have resulted in the incidence of breast cancer continuing to rise, a trend which is expected to continue into the immediate future.

In the UK, breast cancer is the leading type of cancer in women, with there being over 54,900 cases diagnosed each year. Although early-stage cancer is relatively treatable and has good 5- and 10-year disease-free survival rates, 10% of cancers are diagnosed late. Additionally, there are no treatments for metastatic breast cancer, which ultimately results in death.

As a whole, this presents a huge unmet clinical need in the breast cancer treatment algorithm. The treatment algorithm for breast cancer focuses on two main themes: standard chemotherapy and drugs that target hormones, namely estrogen and progesterone. However, chemotherapy and hormone drugs only make up a small percentage of the drug pipeline and an even smaller percentage of first-in-class products.

New trends in oncology are present in the breast cancer pipeline, in particular the focus on extracellular matrix degradation and improving the immune response to tumors. This report focuses on the epidemiology, pathophysiology and existing treatment options for breast cancer before giving detailed insight into promising pipeline targets and deal activity in the breast cancer market.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1877885

Scope

- Unmet need is extremely high in late-stage breast cancer.

- What are the most important etiological risk factors and pathophysiological processes implicated in breast cancer?

- What is the current treatment algorithm?

- How effective are current therapies for these indications, and how does this impact prognosis?

- The breast cancer pipeline is large and contains a very high proportion of first-in-class product innovation.

- Which molecule types and molecular targets are most prominent across the breast cancer pipeline?

- What are the relationships between established and up-coming molecular targets in breast cancer?

- Which first-in-class targets are most promising?

- How does first-in-class target diversity differ by stage of development and molecular target class?

- The deals landscape is active and dominated by very high and very low deal values.

- Which indications attract the highest deal values?

- How has deal activity fluctuated over the past decade?

- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Browse TOC @ https://www.researchmoz.us/frontier-pharma-breast-cancer-first-in-class-innovation-underlies-immunotherapeutic-potential-and-pipeline-diversification-for-late-stage-breast-cancer-report.html/toc

Reasons to buy

- Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.

- Identify leading products and key unmet needs within the market.

- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential.

- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

Various Treatment Options Available For Breast Cancer Focuses On Two Main Themes: Standard Chemotherapy And Estrogen And Progesterone

Researchmoz added Most up-to-date research on "Various Treatment Options Available For Breast Cancer Focuses On Two Main Themes: Standard Chemotherapy And Estrogen And Progesterone" to its huge collection of research reports.

Breast cancer remains a major global healthcare concern despite exceptional levels of public awareness about the disease. A lack of clear causative environmental factors and hereditary dispositioning have resulted in the incidence of breast cancer continuing to rise, a trend which is expected to continue into the immediate future.

In the UK, breast cancer is the leading type of cancer in women, with there being over 54,900 cases diagnosed each year. Although early-stage cancer is relatively treatable and has good 5- and 10-year disease-free survival rates, 10% of cancers are diagnosed late. Additionally, there are no treatments for metastatic breast cancer, which ultimately results in death.

As a whole, this presents a huge unmet clinical need in the breast cancer treatment algorithm. The treatment algorithm for breast cancer focuses on two main themes: standard chemotherapy and drugs that target hormones, namely estrogen and progesterone. However, chemotherapy and hormone drugs only make up a small percentage of the drug pipeline and an even smaller percentage of first-in-class products.

New trends in oncology are present in the breast cancer pipeline, in particular the focus on extracellular matrix degradation and improving the immune response to tumors. This report focuses on the epidemiology, pathophysiology and existing treatment options for breast cancer before giving detailed insight into promising pipeline targets and deal activity in the breast cancer market.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1877885

Scope

- Unmet need is extremely high in late-stage breast cancer.
- What are the most important etiological risk factors and pathophysiological processes implicated in breast cancer?
- What is the current treatment algorithm?
- How effective are current therapies for these indications, and how does this impact prognosis?
- The breast cancer pipeline is large and contains a very high proportion of first-in-class product innovation.
- Which molecule types and molecular targets are most prominent across the breast cancer pipeline?
- What are the relationships between established and up-coming molecular targets in breast cancer?
- Which first-in-class targets are most promising?
- How does first-in-class target diversity differ by stage of development and molecular target class?
- The deals landscape is active and dominated by very high and very low deal values.
- Which indications attract the highest deal values?
- How has deal activity fluctuated over the past decade?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Browse TOC @ https://www.researchmoz.us/frontier-pharma-breast-cancer-first-in-class-innovation-underlies-immunotherapeutic-potential-and-pipeline-diversification-for-late-stage-breast-cancer-report.html/toc

Reasons to buy

- Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

New Study On Breast Cancer Market: Global Industry Analysis & Outlook, 2017 - 2021

Researchmoz added Most up-to-date research on "New Study On Breast Cancer Market: Global Industry Analysis & Outlook, 2017 - 2021" to its huge collection of research reports.

Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also instigate in the stromal tissues, which include the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, radiation therapy, family history and personal history are linked to the growth of breast cancer.

The global market for breast cancer has grown swiftly over the past few years driven by introduction of several new drugs and biosimilars. The overall breast cancer market remained mainly dominated by the generic drugs. The future market for breast cancer will grow in the coming years as there exist unmet need for new drugs that would overcome resistance and prevent recurrence of the disease.

The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, clinical trials of CDK4/6 inhibitors and introduction of new imaging tests. However, growth of the market can be hindered by several factors including drug development challenges in developing countries, long term side effects of drugs and heavy costs associated with drug development.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=964493

The report “Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.

Table of Content

1. Introduction
1.1 Market Overview

2. Global Breast Cancer Market
2.1 Global Breast Cancer Market by Value
2.2 Global Breast Cancer Market Forecast by Value
2.3 Global Breast Cancer Market by Region
2.4 Global Breast Cancer Drug Development by Stages

3. Regional Breast Cancer Market
3.1 The U.S.
3.1.1 The U.S. Breast Cancer Market by Value
3.1.2 The U.S. Breast Cancer Market Forecast by Value
3.1.3 The U.S. Breast Cancer Market by Addressable Population
3.1.4 The U.S. Breast Cancer Market Forecast by Addressable Population
3.1.5 The U.S. Breast Cancer Population by Age

Browse More Details @ https://www.researchmoz.us/global-breast-cancer-market-industry-analysis-outlook-20172021-report.html

Southeast Asia's Breast Cancer Therapeutics Market to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

Researchmoz added Most up-to-date research on "Southeast Asia's Breast Cancer Therapeutics Market to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market" to its huge collection of research reports.

Breast cancer is a malignant neoplasm that begins in the breast tissue. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Broadly, patients can be segmented into two types: the human epidermal growth factor receptor (HER) 2-negative segment and the HER2-positive segment. HER2-positive breast cancer is aggressive and, historically, has had a worse overall survival than HER2-negative disease, which is considered less aggressive.

In HER2-negative breast cancer, a number of different factors can influence the choice of therapy that a patient receives, including the stage of the cancer, the hormonal receptor status of the cancer (ER-positive or -negative and PR-positive or -negative) and whether the patient is a BRCA-mutation carrier. Triple-negative breast cancer (TNBC) is a setting with incredibly high unmet needs, with no targeted therapy options being available. Chemotherapy is the mainstay of treatment in this setting. For HR-positive disease, endocrine therapies are the primary treatment.

Survival for HER2-positive breast cancer patients has increased, due to established disease management strategies using numerous combinations of chemotherapy along with targeted therapies such as Herceptin, Tykerb (lapatinib) and Perjeta (pertuzumab). These newer therapies are expected to significantly improve survival outcomes in all lines of the disease. The introduction of Herceptin, the first HER2-targeting agent for metastatic disease, greatly improved the outcome of patients with HER2-positive breast cancer, bringing survival rates close to those of HER2-negative, HR-positive breast cancer.

In most Southeast Asian countries, the highest unmet need lies in the lack of a defined treatment plan for the disease, poor affordability, and patients continuing to rely on the use of chemotherapies in the later lines of treatment. It is important for drug companies to consider the evolving reimbursement landscape when determining pricing strategies across the Southeast Asian markets, because this will significantly impact the uptake of premium drugs.

Scope

The current Southeast Asia breast cancer market contains well-established novel targeted products such as Perjeta and Kadcyla, tyrosine kinase inhibitors such as Tykerb, and CDK inhibitors such as Ibrance.

• Which drugs are used as the standard treatment in each setting of the disease?
• What are the competitive advantages of the existing novel drugs?
• Do branded therapies show continued growth, and how does their expected uptake influence the market growth over the forecast period?

There are about 1,150 active pipeline molecules. The pipeline contains a range of molecule types and molecular targets, including those that are well established in breast cancer, and novel, first-in-class therapies.

• Which molecular targets appear most frequently in the pipeline?
• There is currently no approved therapy in the TNBC setting. Are there any drugs in the pipeline to improve treatment for TNBC?
• Targets that are not currently represented by marketed products are virtually absent from the late-stage pipeline. Does the early stage pipeline have experimental molecules designed to target novel pathways?

Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II, at 59%, with the overall attrition rate for breast cancer standing at 85%.

• How do failure rates vary by stage of development, molecule type, and molecular target?
• How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

The breast cancer Southeast Asian market will be valued at $2.7 billion in 2022, growing from $942.3m in 2015 at a CAGR of 16.2%.

• Despite an array of treatments being available for breast cancer, there is still an unmet need in the Southeast Asian markets related to low uptake of targeted therapies. Will this scenario change during the forecast period?

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1068037

Market forecasts indicate that South Korea will continue to be the largest market in Southeast Asia, due to the emergence of novel therapies and the continued uptake of branded therapies.

• How will the annual cost of therapy and market size vary between the eight Southeast Asian markets? 
• What are the factors that contribute to the increase in ACoT and market size for each of the assessed countries?
• How will branded therapies be affected by upcoming pipeline therapies in each of the assessed countries?
• How will the potential launch of biosimilars influence each country? 
• Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?

Various drivers and barriers will influence the market over the forecast period.

• What barriers limit the uptake of premium-priced therapeutics in the assessed countries?
• What factors are most likely to drive the market in these countries?

Reasons to buy

This report will allow you to - 

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
• Visualize the composition of the breast cancer market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are also highlighted to allow a competitive understanding of gaps in the market.
• Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
• Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict breast cancer market growth in the eight Southeast Asian markets, with epidemiological and annual cost of therapy forecasts, as well as analysis of the contributions of promising late-stage molecules to market growth. 
• Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.

Browse More Details @ http://www.researchmoz.us/breast-cancer-therapeutics-in-southeast-asia-markets-to-2022-increasing-prevalence-and-usage-of-premium-targeted-therapies-to-drive-the-market-report.html

Diagnostic Tests For Breast Cancer: Medical Devices Pipeline Assessment, 2017

Researchmoz added Most up-to-date research on "Diagnostic Tests For Breast Cancer: Medical Devices Pipeline Assessment, 2017" to its huge collection of research reports.

GlobalData's Medical Devices sector report, Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" provides an overview of Breast Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Breast Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Breast Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Breast Cancer Diagnostic Tests and list all their pipeline projects

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=885316

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to - 
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Breast Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=885316